E. Goetz

发表

Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016, Cell reports.

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Dennis C. Friedrich, A. McKenna, K. Cibulskis, 2014, Cancer discovery.

ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability

B. Shankar, E. Goetz, L. Mayo, 2011, Oncogene.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Levi A Garraway, Kwok-Kin Wong, Neal Rosen, 2012, Cancer discovery.

Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma.

L. Garraway, E. Goetz, Eva M. Goetz, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Signal transduction processes in response to low dose ionizing radiation doses expected during space flight

E. Goetz, D. Boothman, T. Criswell, 2013 .

Cellular Stress Responses to DNA Damage: An Intracellular Balance between Life, Senescence, and Death

E. Goetz, L. Mayo, M. Jackson, 2011 .

Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect

E. Goetz, D. Boothman, S. Araki, 2012, Oncogene.

Low dose IR-induced IGF-1-sCLU expression: a p53-repressed, TGFß1-induced expression cascade that interferes with TGFß1 signaling to confer survival

E. Goetz, D. Boothman, S. Araki, 2011 .

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

A. McKenna, K. Cibulskis, S. Gabriel, 2014, Cancer discovery.

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.

Simion I. Chiosea, Kelsey P. Pendleton, A. McKenna, 2015, JAMA oncology.

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

L. Garraway, D. Treacy, M. Ghandi, 2014, Cancer research.

Phenotypic Characterizati on of a Comprehensive Set of MAPK 1 / ERK 2 Missense Mutants Graphical

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016 .

Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition.

S. Gabriel, S. Carter, L. Garraway, 2013 .

Secretory Clusterin Is a Marker of Tumor Progression Regulated by IGF-1 and Wnt Signaling Pathways

E. Goetz, D. Boothman, Masatoshi Suzuki, 2009 .

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

A. Letai, L. Garraway, P. Jänne, 2012, Cancer discovery.